

# Yasuhiro Matsumura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9255539/publications.pdf>

Version: 2024-02-01

119  
papers

6,103  
citations

87401

40  
h-index

81351

76  
g-index

127  
all docs

127  
docs citations

127  
times ranked

7823  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase. <i>Thrombosis and Haemostasis</i> , 2022, 122, 057-066.	1.8	3
2	The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3. <i>Translational Oncology</i> , 2022, 15, 101285.	1.7	1
3	35 years of discussions with Prof. Maeda on the EPR effect and future directions. <i>Journal of Controlled Release</i> , 2022, 348, 966-969.	4.8	9
4	High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 302.	1.1	11
5	Radioimmunotherapy with an <sup>211</sup> At-labeled anti-tissue factor antibody protected by sodium ascorbate. <i>Cancer Science</i> , 2021, 112, 1975-1986.	1.7	12
6	Barriers to antibody therapy in solid tumors, and their solutions. <i>Cancer Science</i> , 2021, 112, 2939-2947.	1.7	13
7	TMEM180 contributes to SW480 human colorectal cancer cell proliferation through intra-cellular metabolic pathways. <i>Translational Oncology</i> , 2021, 14, 101186.	1.7	1
8	Cancer stromal targeting therapy to overcome the pitfall of EPR effect. <i>Advanced Drug Delivery Reviews</i> , 2020, 154-155, 142-150.	6.6	28
9	Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytotoxic effects. <i>Journal of Controlled Release</i> , 2020, 323, 138-150.	4.8	14
10	Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumors. <i>Journal of Controlled Release</i> , 2020, 323, 519-529.	4.8	10
11	Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus. <i>Blood</i> , 2020, 135, 1969-1982.	0.6	17
12	Contribution from Synthetic Organic Chemistry and Glycoscience to ADC Development: Homogeneous ADC Preparation and Development of Cancer Stromal Targeting Therapy. Yuki Gosei Kagaku Kyokai/Journal of Synthetic Organic Chemistry, 2020, 78, 485-494.	0.0	0
13	Thinking about The Japan Society of DDS. <i>Drug Delivery System</i> , 2020, 35, 3-3.	0.0	0
14	Selection of Tumor models. <i>Drug Delivery System</i> , 2020, 35, 443-447.	0.0	0
15	Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer. <i>Oncology Letters</i> , 2019, 17, 831-842.	0.8	10
16	Topological analysis of TMEM180, a newly identified membrane protein that is highly expressed in colorectal cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2019, 520, 566-572.	1.0	12
17	Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models. <i>Cancer Science</i> , 2019, 110, 3296-3305.	1.7	11
18	Anti-tissue factor antibody-mediated immuno-SPECT imaging of tissue factor expression in mouse models of pancreatic cancer. <i>Oncology Reports</i> , 2019, 41, 2371-2378.	1.2	8

#	ARTICLE	IF	CITATIONS
19	Characterization of Antibody Products Obtained through Enzymatic and Nonenzymatic Glycosylation Reactions with a Glycan Oxazoline and Preparation of a Homogeneous Antibody-Drug Conjugate via Fc <i>N</i> -Glycan. <i>Bioconjugate Chemistry</i> , 2019, 30, 1343-1355.	1.8	30
20	ET-05 PRECLINICAL STUDY OF AN ANTI-HUMAN TISSUE FACTOR ANTIBODY-DRUG CONJUGATE IN A MALIGNANT GLIOMA XENOGRAFT MODEL. <i>Neuro-Oncology Advances</i> , 2019, 1, ii9-ii9.	0.4	0
21	Preclinical Studies of ADC Therapy for Solid Tumors. , 2019, , 125-154.		0
22	Significant antitumor effect of an antibody against TMEM180, a new colorectal cancer-specific molecule. <i>Cancer Science</i> , 2019, 110, 761-770.	1.7	20
23	Principle of CAST Strategy. , 2019, , 255-267.		2
24	Cancer and Blood Coagulation. , 2019, , 23-40.		2
25	Preclinical studies of immunomicelles incorporating anticancer drugs. <i>Drug Delivery System</i> , 2019, 34, 29-37.	0.0	0
26	CAST Therapy. , 2019, , 269-288.		0
27	The Current Status of Cancer Drug Delivery Systems and Future Directions. , 2019, , 311-319.		0
28	Targeting anticoagulant protein S to improve hemostasis in hemophilia. <i>Blood</i> , 2018, 131, 1360-1371.	0.6	57
29	Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody. <i>World Journal of Gastroenterology</i> , 2018, 24, 5491-5504.	1.4	26
30	A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 1021-1029.	1.1	32
31	Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin. <i>Scientific Reports</i> , 2018, 8, 14211.	1.6	31
32	Tuned Density of Anti-Tissue Factor Antibody Fragment onto siRNA-Loaded Polyion Complex Micelles for Optimizing Targetability into Pancreatic Cancer Cells. <i>Biomacromolecules</i> , 2018, 19, 2320-2329.	2.6	34
33	Collagen type I induces <i>EGFR</i> resistance in <i>TKI</i> resistance in <i>EGFR</i> mutated cancer cells by <i>mTOR</i> activation through Akt-independent pathway. <i>Cancer Science</i> , 2018, 109, 2063-2073.	1.7	39
34	Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. <i>Journal of Controlled Release</i> , 2018, 284, 49-56.	4.8	48
35	Development of CAST therapy based on the EPR effect: lesson from clinical trials.. <i>Drug Delivery System</i> , 2018, 33, 139-149.	0.0	2
36	Mass spectrometry imaging for early discovery and development of cancer drugs. <i>AIMS Medical Science</i> , 2018, 5, 162-180.	0.2	2

#	ARTICLE	IF	CITATIONS
37	Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model. <i>Scientific Reports</i> , 2017, 7, 12341.	1.6	20
38	Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. <i>Scientific Reports</i> , 2017, 7, 10735.	1.6	28
39	Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging. <i>Bioengineering</i> , 2017, 4, 78.	1.6	23
40	Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. <i>Oncotarget</i> , 2017, 8, 11020-11029.	0.8	9
41	High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. <i>Oncotarget</i> , 2017, 8, 6970-6983.	0.8	36
42	Imaging mass spectrometry for the precise design of antibody-drug conjugates. <i>Scientific Reports</i> , 2016, 6, 24954.	1.6	33
43	Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment. <i>Scientific Reports</i> , 2016, 6, 23613.	1.6	33
44	Utility of epirubicin-incorporating micelles tagged with anti-tissue factor antibody clone with no anticoagulant effect. <i>Cancer Science</i> , 2016, 107, 335-340.	1.7	18
45	Development of polymeric micelles for targeting intractable cancers. <i>Cancer Science</i> , 2016, 107, 867-874.	1.7	149
46	Effect of combined treatment with micelle-incorporated cisplatin (NC-6004) and S-1 on human gastric cancer xenografts. <i>Molecular and Clinical Oncology</i> , 2016, 5, 817-822.	0.4	4
47	Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 750-759.	1.2	28
48	Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. <i>BMC Cancer</i> , 2015, 15, 718.	1.1	11
49	Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. <i>International Journal of Cancer</i> , 2015, 137, 1457-1466.	2.3	62
50	Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models. <i>Cancer Science</i> , 2015, 106, 627-634.	1.7	35
51	Feasibility study of the Fab fragment of a monoclonal antibody against tissue factor as a diagnostic tool. <i>International Journal of Oncology</i> , 2015, 47, 2107-2114.	1.4	17
52	General considerations regarding the in vitro and in vivo properties of block copolymer micelle products and their evaluation. <i>Journal of Controlled Release</i> , 2015, 210, 76-83.	4.8	63
53	Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. <i>Biomaterials</i> , 2015, 39, 23-30.	5.7	125
54	Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect. <i>PLoS ONE</i> , 2014, 9, e105160.	1.1	5

#	ARTICLE	IF	CITATIONS
55	The initiatives for regulatory science researches of nanomedicines. <i>Drug Delivery System</i> , 2014, 29, 217-225.	0.0	2
56	Marked antitumor effect of NK012, a SN-38-incorporating micelle formulation, in a newly developed mouse model of liver metastasis resulting from gastric cancer. <i>Therapeutic Delivery</i> , 2014, 5, 129-138.	1.2	8
57	Effect of combined treatment with the epirubicin-incorporating micelles (NC6300) and 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC4016) on a human gastric cancer model. <i>International Journal of Cancer</i> , 2014, 135, 214-223.	2.3	35
58	New molecular diagnosis and screening methods for colorectal cancer using fecal protein, DNA and RNA. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 107-120.	1.5	7
59	Preparation and characterization of anti-tissue factor single-chain variable fragment antibody for cancer diagnosis. <i>Cancer Science</i> , 2014, 105, 1631-1637.	1.7	10
60	The Drug Discovery by NanoMedicine and its Clinical Experience. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 515-525.	0.6	75
61	Role of SLC6A6 in promoting the survival and multidrug resistance of colorectal cancer. <i>Scientific Reports</i> , 2014, 4, 4852.	1.6	35
62	A clinical trial can determine the course of DDS development. <i>Drug Delivery System</i> , 2014, 29, 39-50.	0.0	1
63	Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. <i>Journal of Bioscience and Bioengineering</i> , 2013, 116, 768-773.	1.1	8
64	Fecal miR-106a Is a Useful Marker for Colorectal Cancer Patients with False-Negative Results in Immunochemical Fecal Occult Blood Test. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1844-1852.	1.1	73
65	Discovery of an uncovered region in fibrin clots and its clinical significance. <i>Scientific Reports</i> , 2013, 3, 2604.	1.6	44
66	Development of a diketopiperazine-forming dipeptidyl Gly-Pro spacer for preparation of an antibody-drug conjugate. <i>MedChemComm</i> , 2013, 4, 792.	3.5	19
67	Application of the Fecal MicroRNA Test to the Residuum from the Fecal Occult Blood Test. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 726-733.	0.6	17
68	NC6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. <i>Cancer Science</i> , 2013, 104, 920-925.	1.7	114
69	Tailored immunoconjugate therapy depending on a quantity of tumor stroma. <i>Cancer Science</i> , 2013, 104, 231-237.	1.7	28
70	The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution. <i>Scientific Reports</i> , 2013, 3, 3050.	1.6	39
71	Tumor stromal barrier and cancer stromal targeting therapy. <i>Microvascular Reviews and Communications</i> , 2013, 6, 2-8.	0.0	3
72	Clinical development of anticancer agents incorporating micelles in oncological treatment. <i>Drug Delivery System</i> , 2013, 28, 215-220.	0.0	1

#	ARTICLE	IF	CITATIONS
73	Cancer Stromal Targeting (CAST) Therapy and Tailored Antibody Drug Conjugate Therapy Depending on the Nature of Tumor Stroma. , 2013, , 161-181.		0
74	Cancer Stromal Targeting. Drug Delivery System, 2013, 28, 396-405.	0.0	0
75	Application of miRNA expression analysis on exfoliated colonocytes for diagnosis of colorectal cancer. Gastrointestinal Cancer: Targets and Therapy, 2012, , 11.	5.5	1
76	Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Investigational New Drugs, 2012, 30, 1621-1627.	1.2	213
77	Cancer stromal targeting (CAST) therapy. Advanced Drug Delivery Reviews, 2012, 64, 710-719.	6.6	99
78	Cancer-Stroma Targeting Therapy by Cytotoxic Immunoconjugate Bound to the Collagen 4 Network in the Tumor Tissue. Bioconjugate Chemistry, 2011, 22, 1776-1783.	1.8	70
79	The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody. European Journal of Cancer, 2011, 47, 2230-2239.	1.3	41
80	Clinical development of nano-DDS. Drug Delivery System, 2011, 26, 20-28.	0.0	0
81	Novel virtual cytological analysis for the detection of endometrial cancer cells using autoscan fluoromicroscopy. Cancer Science, 2011, 102, 1068-1075.	1.7	3
82	New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. Cancer Science, 2011, 102, 1396-1402.	1.7	69
83	EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Advanced Drug Delivery Reviews, 2011, 63, 129-130.	6.6	193
84	Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Advanced Drug Delivery Reviews, 2011, 63, 184-192.	6.6	205
85	Exosome can prevent RNase from degrading microRNA in feces. Journal of Gastrointestinal Oncology, 2011, 2, 215-22.	0.6	145
86	Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemotherapy and Pharmacology, 2010, 66, 95-105.	1.1	55
87	The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer, 2010, 116, 4597-4604.	2.0	22
88	Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer. International Journal of Cancer, 2010, 127, 2699-2706.	2.3	21
89	Detailed Distribution of NK012, an SN-38-incorporating Micelle, in the Liver and Its Potent Antitumor Effects in Mice Bearing Liver Metastases. Clinical Cancer Research, 2010, 16, 4822-4831.	3.2	24
90	MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening. Cancer Prevention Research, 2010, 3, 1435-1442.	0.7	197

#	ARTICLE	IF	CITATIONS
91	Phase I Study of NK012, a Novel SN-38 Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 5058-5066.	3.2	136
92	Antitumor Effect of NK012, a 7-Ethyl-10-Hydroxycamptothecin Incorporating Polymeric Micelle, on U87MG Orthotopic Glioblastoma in Mice Compared with Irinotecan Hydrochloride in Combination with Bevacizumab. <i>Clinical Cancer Research</i> , 2010, 16, 521-529.	3.2	35
93	Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour. <i>European Journal of Cancer</i> , 2010, 46, 650-658.	1.3	26
94	Cancer Chemotherapy by DDS. <i>Oleoscience</i> , 2010, 10, 25-30.	0.0	0
95	Antitumor Activity of NK012 Combined with Cisplatin against Small Cell Lung Cancer and Intestinal Mucosal Changes in Tumor-Bearing Mouse after Treatment. <i>Clinical Cancer Research</i> , 2009, 15, 4348-4355.	3.2	38
96	Potent antitumor effect of SN-38 incorporating polymeric micelle, NK012, against malignant glioma. <i>International Journal of Cancer</i> , 2009, 124, 2505-2511.	2.3	62
97	Preclinical and clinical studies of anticancer agent incorporating polymer micelles. <i>Cancer Science</i> , 2009, 100, 572-579.	1.7	474
98	Synergistic antitumor activity of the novel SN-38 incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. <i>International Journal of Cancer</i> , 2008, 122, 2148-2153.	2.3	53
99	Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 899-914.	6.6	253
100	Enhanced distribution of NK012, a polymeric micelle encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. <i>Cancer Science</i> , 2008, 99, 1258-1264.	1.7	42
101	Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. <i>Cancer Science</i> , 2008, 99, 1977-1983.	1.7	34
102	Polymeric Micellar Delivery Systems in Oncology. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 793-802.	0.6	114
103	Antitumor Effect of SN-38 Releasing Polymeric Micelles, NK012, on Spontaneous Peritoneal Metastases from Orthotopic Gastric Cancer in Mice Compared with Irinotecan. <i>Cancer Research</i> , 2008, 68, 9318-9322.	0.4	43
104	Novel SN-38 Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression. <i>Cancer Research</i> , 2008, 68, 1631-1635.	0.4	61
105	New method for colorectal cancer diagnosis based on SSCP analysis of DNA from exfoliated colonocytes in naturally evacuated feces. <i>Anticancer Research</i> , 2008, 28, 145-50.	0.5	9
106	Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. <i>Journal of Human Genetics</i> , 2007, 52, 804-819.	1.1	51
107	Novel SN-38 Incorporating Polymeric Micelles, NK012, Eradicate Vascular Endothelial Growth Factor Secreting Bulky Tumors. <i>Cancer Research</i> , 2006, 66, 10048-10056.	0.4	234
108	A New Method for Isolating Colonocytes From Naturally Evacuated Feces and Its Clinical Application to Colorectal Cancer Diagnosis. <i>Gastroenterology</i> , 2005, 129, 1918-1927.	0.6	55

#	ARTICLE	IF	CITATIONS
109	Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. <i>Cancer Science</i> , 2004, 95, 608-613.	1.7	74
110	Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. <i>Cancer Research</i> , 2003, 63, 8977-83.	0.4	486
111	Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil). <i>Japanese Journal of Cancer Research</i> , 2002, 93, 1145-1153.	1.7	100
112	Incorporation of the Anticancer Agent KRN5500 into Polymeric Micelles Diminishes the Pulmonary Toxicity. <i>Japanese Journal of Cancer Research</i> , 2002, 93, 1237-1243.	1.7	28
113	Cisplatin-incorporated Polymeric Micelles Eliminate Nephrotoxicity, While Maintaining Antitumor Activity. <i>Japanese Journal of Cancer Research</i> , 2001, 92, 328-336.	1.7	86
114	Reduction of the Side Effects of an Antitumor Agent, KRN5500, by Incorporation of the Drug into Polymeric Micelles. <i>Japanese Journal of Cancer Research</i> , 1999, 90, 122-128.	1.7	49
115	Incorporation of water-insoluble anticancer drug into polymeric micelles and control of their particle size. <i>Journal of Controlled Release</i> , 1998, 55, 219-229.	4.8	186
116	Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer. <i>Gastroenterology</i> , 1998, 114, 1196-1205.	0.6	59
117	Kinin-generating Cascade in Advanced Cancer Patients and in vitro Study. <i>Japanese Journal of Cancer Research</i> , 1991, 82, 732-741.	1.7	99
118	Involvement of the Kinin-generating Cascade in Enhanced Vascular Permeability in Tumor Tissue. <i>Japanese Journal of Cancer Research</i> , 1988, 79, 1327-1334.	1.7	150
119	Trends of food consumption pattern reflected upon economic growth. [ <i>Minzoku Eisei</i> ] <i>Race Hygiene</i> , 1981, 47, 138-147.	0.0	0